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Drug liking vs. drug disliking is a subjective motivational measure in humans that
assesses the addiction liability of drugs. Variation in this trait is hypothesized to influence
vulnerability vs. resilience toward substance abuse disorders and likely contains a genetic
component. In rodents and humans, conditioned place preference (CPP)/aversion (CPA)
is a Pavlovian conditioning paradigm whereby a learned preference for the drug-paired
environment is used to infer drug liking whereas a learned avoidance or aversion is used
to infer drug disliking. C57BL/6 inbred mouse substrains are nearly genetically identical,
yet demonstrate robust differences in addiction-relevant behaviors, including locomotor
sensitization to cocaine and consumption of ethanol. Here, we tested the hypothesis
that B6 substrains would demonstrate differences in the rewarding properties of the
mu opioid receptor agonist oxycodone (5mg/kg, i.p.) and the aversive properties of
the opioid receptor antagonist naloxone (4mg/kg, i.p.). Both substrains showed similar
degrees of oxycodone-induced CPP; however, there was a three-fold enhancement of
naloxone-induced CPA in agonist-naïve C57BL/6J relative to C57Bl/6NJ mice. Exploratory
factor analysis of CPP and CPA identified unique factors that explain variance in
behavioral expression of reward vs. aversion. “Conditioned Opioid-Like Behavior” was
a reward-based factor whereby drug-free locomotor variables resembling opioid treatment
co-varied with the degree of CPP. “Avoidance and Freezing” was an aversion-based
factor, whereby the increase in the number of freezing bouts co-varied with the degree
of aversion. These results provide new insight into the behavioral architecture of the
motivational properties of opioids. Future studies will use quantitative trait locus mapping
in B6 substrains to identify novel genetic factors that contribute to the marked strain
difference in NAL-CPA.
Keywords: factor analysis, motivated behavior, opioid, euphoria, dysphoria, naltrexone, substrain, quantitative
trait locus
INTRODUCTION
Opioids, including the prescription mu opioid receptor agonist
oxycodone (OXY) are powerfully addictive substances. The non-
medical abuse of OXY fueled the two-fold increase in heroin use
and dependence between 2007 and 2011 (http://www.samhsa.
gov/) and opioid abuse has now reached epidemic proportions
(Atluri et al., 2014; Mars et al., 2014). The addictions are heritable
psychiatric diseases (Goldman et al., 2005; Ho et al., 2010; Ducci
and Goldman, 2012); however, the major genetic factors have yet
to be identified. Substance use disorders are defined by an aggre-
gate of symptoms that can vary across time in their presence and
severity. Many of these traits are likely to have different genetic
architectures, making it difficult to identify the underlying causal
factors of the addicted state.
The degree of subjective drug “liking” that individuals expe-
rience following drug administration is an intuitively simple
Abbreviations: SAL, saline; OXY, oxycodone; NAL, naloxone; CPP, conditioned
place preference; CPA, conditioned place aversion; QTL, quantitative trait locus;
D4-D2, Day 4—Day 2; D8-D1, Day 8—Day 1; D9-D1, Day 9—Day 1; B6, C57BL/6;
J, C57BL/6J; NJ, C57BL/6NJ.
phenotype that could influence susceptibility toward opioid
addiction (Haertzen et al., 1983) and has been used to infer the
addiction liability of opioids, including OXY formulations (Setnik
et al., 2011; Webster et al., 2012). There is substantial varia-
tion among individuals with regard to opioid liking, with some
individuals even reporting a clear disliking; interestingly, opioid
disliking appears to have a stronger genetic component (Angst
et al., 2012). An overarching hypothesis is that genetic factors
responsible for variation in opioid liking vs. disliking contribute
to individual differences in opioid addiction liability.
In model organisms and humans, drug reward can be assessed
using a Pavlovian conditioning procedure known as condi-
tioned place preference/conditioned place aversion (CPP/CPA)
(Tzschentke, 2007; Childs and de Wit, 2009, 2013). Here, dis-
tinct environmental cues are explicitly paired with a context
where either drug or saline (SAL) is administered and follow-
ing repeated intermittent trials, subjects are subsequently given
a choice between preference for or avoidance of the drug or
SAL-paired environment. CPP for the drug-paired environment
is predicted by self-reported measures of drug liking in humans
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(Childs and de Wit, 2009) and is used to infer the addiction
liability of opioids (Hunter and Reid, 1983). CPA for the drug-
paired environment is used to infer the dysphoric properties of
drugs, including opioid receptor antagonists (Martin del Campo
et al., 1992).
In contrast to mu opioid receptor agonists such as OXY
that produce CPP (Bryant et al., 2012a), opioid receptor antag-
onists such as naloxone (NAL) produce a conditioned place
aversion for the drug-paired environment (Mucha and Iversen,
1984; Mucha et al., 1985; Burgdorf et al., 2001; Sakoori and
Murphy, 2004, 2005; Shoblock and Maidment, 2006). NAL-CPA
requires mu opioid receptors (Skoubis et al., 2001) and endoge-
nous enkephalins (Skoubis et al., 2005) but does not require D1
or D2 dopamine receptors (Narayanan et al., 2004). Sensitivity to
NAL-CPA is greatly enhanced by prior chronic administration of
mu opioid receptor agonists (Shoblock andMaidment, 2006) and
represents amodel for the negative affective-motivational compo-
nent of opioid withdrawal (Schulteis et al., 1994). Furthermore,
NAL and the closely related compound naltrexone cause dys-
phoria in a subset of human subjects, including healthy human
volunteers (Martin del Campo et al., 1992) and opioid addicts
(Crowley et al., 1985; Malcolm et al., 1987; Handelsman et al.,
1992; Kanof et al., 1992). Finally, opioid receptor antagonists are
used to treat craving in a subset of alcoholic patients (Oslin et al.,
2006; Ray et al., 2010). Thus, an improved understanding of the
genetic and neurobehavioral basis of both opioid reward and
aversion has therapeutic relevance for prevention and treatment
strategies in opioid and alcohol dependence.
Here, we present a detailed analysis of OXY-CPP and NAL-
CPA in closely related C57BL/6 mouse substrains. C57BL/6J and
C57BL/6NJ are nearly genetically identical (Keane et al., 2011),
yet show robust behavioral differences in behavioral phenotypes
relevant to psychiatric disorders (Bryant et al., 2008), which
greatly facilitates the ability to map the underlying genetic fac-
tors (Bryant, 2011; Kumar et al., 2013). We examined standard
CPP/CPA behavioral measures such as the change in time spent
on the drug-paired side (Bryant et al., 2012a) in the context of
other motivationally relevant behaviors, including the change in
distance, number of visits, mean visit time, and freezing bouts on
the side of preference (OXY) vs. the side of retreat (NAL) during
the drug-free and drug-induced (state-dependent) OXY-CPP and
NAL-CPA, respectively. Exploratory factor analysis was used for
each strain following the induction of OXY-CPP vs. NAL-CPA in
an effort to reduce a large number of variables into a smaller set
of common factors. Here, we wished to gain new insight into the
behavioral architecture that differentiates reward from aversion
and to identify potential genetic differences.
MATERIALS AND METHODS
MICE
All experiments were performed in accordance with the National
Institutes of Health Guidelines for the Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use
Committee at Boston University. Female and male C57BL/6J and
C57BL/6NJ mice were ordered from the Jackson Laboratory (Bar
Harbor, ME USA) and were 8 weeks old at the beginning of
behavioral testing. Upon arrival, mice were housed 2–4 per cage
in standard shoebox-sized cages and were acclimated for 1 week
to the vivarium. Mice were tested during the light phase of the
light/dark cycle between 0800 and 1600 h. A 12 h/12 h light/dark
cycle (lights off at 1830) was used for animal housing in the vivar-
ium. Sample sizes for each treatment, strain, and sex are listed in
Tables 1, 3.
DRUGS
OXY was purchased from Sigma-Aldrich (St. Louis, MO) and
NAL was purchased from Tocris Bioscience (Bristol, UK). The
dose of OXY (5mg/kg, i.p.) was chosen based on our previous
study (Bryant et al., 2012a) and based on several other stud-
ies employing similar doses (3–10mg/kg) to induce a reliable
CPP (Liu et al., 2009; Rutten et al., 2010, 2011a,b; Niikura et al.,
2013). Furthermore, pilot data from both strains indicated amore
pronounced CPP and locomotor stimulatory effect of 5mg/kg
Table 1 | Change in behavior on the OXY-paired preference side (right
side) following SAL or OXY training.
SAL training
Variable J (S.E.M.) NJ (S.E.M.)
N = 56 N = 45
(30 F, 26 M) (25 F, 20 M)
D8-D1 time (s) 17.6 (21.5) 12.1 (23.0)
D8-D1 visit time (s) 1.1 (1.1) 3.5 (3.3)
D8-D1 visits −4.7 (3.5) −0.3 (2.9)
D8-D1 rotations −7.2 (1.3) −4.2 (1.6)
D8-D1 distance (m) −3.9 (1.1) −2.8 (1.1)
D8-D1 freezing bouts 9.8 (16.4) −8.5 (17.0)
D9-D1 time (s) −0.7 (28.0) −3.6 (29.9)
D9-D1 visit time (s) 2.1 (1.0) 1.9 (1.0)
D9-D1 visits −11.4 (4.0) −5.9 (2.6)
D9-D1 rotations −6.8 (2.3) −6.6 (1.7)
D9-D1 distance (m) −6.2 (1.8) −5.6 (1.1)
D9-D1 freezing bouts 7.2 (17.3) 6.4 (15.1)
OXY training
Variable J (S.E.M.) NJ (S.E.M.)
N = 59 N = 55
(29 F, 30 M) (28 F, 27 M)
D8-D1 time (s; CPP) 107.9 (29.9) 105.0 (25.0)
D8-D1 visit time (s) 3.4 (0.9) 1.5 (0.6)
D8-D1 visits −8.1 (2.1) 1.0 (2.7)
D8-D1 rotations −2.2 (1.3) 0.6 (1.4)
D8-D1 distance (m) −1.3 (1.0) 1.2 (0.9)
D8-D1 freezing bouts 35.5 (16.4) 7.7 (18.5)
D9-D1 time (s) 238.7 (34.6) 291.5 (42.9)
D9-D1 visit time (s) −3.2 (3.0) 31.3 (32.6)
D9-D1 visits 161.6 (13.6) 148.3 (17.0)
D9-D1 rotations 189.9 (13.8) 198.7 (15.2)
D9-D1 distance (m) 117.7 (5.9) 116.2 (6.9)
D9-D1 freezing bouts −56.4 (13.7) −45.5 (19.8)
The mean ± S.E.M. and sample size (N; F, females; M, males) for each strain (J,
NJ) and treatment (SAL, OXY) is presented for each of the 12 variables used in
factor analysis.
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OXY relative to lower doses (data not shown). The dose of NAL
(4mg/kg, i.p.) was chosen based on previous studies employ-
ing a dose range of 4–10mg/kg (Skoubis et al., 2001, 2005;
Narayanan et al., 2004; Sakoori and Murphy, 2004, 2005, 2008;
Solecki et al., 2009) and based on pilot studies indicating that this
dose was more effective at inducing CPA than 2mg/kg (data not
shown).
CPP/CPA
We used an unbiased, two-chamber design (Bryant et al.,
2012a,b,c). Mice were recorded in unlit CPP chambers using
infrared cameras (Swann Communications U.S.A., Inc., Sante Fe
Springs, CA, USA) that were mounted to the ceiling of sound
attenuating chambers (Med Associates, St. Albans, VT). Each
Plexiglas side of the chamber was 20 cm in length by 20 cm in
width by 46 cm in height whereby the two sides of the condi-
tioning apparatus (separated by an ion transparent black divider)
differed only in the type of floor texture of the plastic inserts
(Plaskolite, Inc. Columbus, OH) (Figure 1A). Mice were habitu-
ated for a minimum of 1 h in the testing room prior to starting the
experiment. On Day 1, all mice were assessed for initial preference
for the right-paired side (the eventual drug-paired side) whereby
mice received SAL (i.p.), were placed into the left side (the even-
tual SAL-paired side), and were provided free access to both sides
for 30min. On Days 2 and 4, mice received an injection of either
SAL (i.p.), OXY (5mg/kg, i.p.), or NAL (4mg/kg, i.p.) and were
FIGURE 1 | Place conditioning chambers and CPP/CPA design. (A) A
two-chamber design was employed whereby following initial assessment
of preference for each side, drug injections were paired with the right side
and saline injections were paired with the left side. Different floor textures
were used as contextual cues. Notably, the number of rotations (Rot.) was
measured on each side. A rotation was defined by the completion of a
unidirectional, circular sequence across the four zones starting from any
zone number and rotating in either direction (e.g., 1-2-3-4 or 3-2-1-4).
(B) CPP/ CPA protocol. Initial Pref., initial preference for the drug-paired
side; Consolid., consolidation period whereby mice were left undisturbed in
their home cages in the vivarium for 2 days; State-Dep., state-dependent
assessment of OXY-CPP or NAL-CPA whereby mice were administered a
subsequent drug injection and tested for CPP/CPA; D, day of training; SAL,
saline; DRUG, OXY or NAL treatment; -, no treatment was administered.
confined to the right side for 30min. On Days 3 and 5, all mice
received SAL (i.p.) and were confined to the left side for 30min.
Days 6 and 7 served as a 2-day consolidation period whereby mice
were left undisturbed in their home cage in the vivarium. On
Day 8, mice were tested for drug-free CPP/CPA whereby all mice
received SAL (i.p.), were placed into the left side, and were pro-
vided free access to both sides for 30min (Figure 1B). On Day
9 mice were tested for state-dependent CPP/CPA (Mucha and
Iversen, 1984) whereby mice were injected with the same treat-
ment they received during drug training on Days 2 and 4 (SAL,
OXY, or NAL; Figure 1B). Behavioral data were tracked using
Anymaze video tracking software (Stoelting Co., Wood Dale, IL).
Our primary outcome variables for the study included the change
in time spent on the drug-paired side between Days 1 and 8 (D8-
D1; drug-free CPP/CPA) and between Days 1 and 9 (D9-D1;
state-dependent CPP/CPA). Additional variables were measured
as described below. Data were exported to an Excel spreadsheet,
curated into a dataframe, and statistically analyzed in R (http://
www.r-project.org/).
BEHAVIORAL ANALYSIS
We examined potential strain differences in drug-induced
responses between drug training Days 2 and 4 (D4-
D2; Figure 1B). In considering D4-D2 distance, rotations
(Figure 1A), and freezing bouts, we ran Three-Way ANOVAs
(Treatment, Strain, Sex). There were always two levels of treat-
ment; either OXY vs. SAL or NAL vs. SAL. Two-way interactions
(Treatment, Strain) were further investigated with t-tests using
significance thresholds that were Bonferroni-corrected for the
number of specified comparisons (see below).
With regard to the subtraction variables for OXY vs. SAL, we
wanted to know the behavioral structure of the expression of opi-
oid reward; thus, we focused on the OXY (right)-paired side—the
preference side. With regard to NAL vs. SAL, we wanted to know
the behavioral structure comprising opioid avoidance / aversion;
thus for this analysis, we turned our focus toward the SAL-paired
side which we refer to as the side of retreat. Our rationale behind
using the SAL-paired side as the point of reference for NAL-
induced conditioned aversive behaviors is that in this case, the
non-drug side is where the mice spent a majority of their time
“behaving” during CPA assessment and presumably where the
motivational expression of aversion/dysphoria occurs. Thus, we
felt it was most appropriate to examine the behavior in the spe-
cific environment where the mice are expressing the avoidance of
NAL, or i.e., the side of retreat (just as we are examining the spe-
cific environment where the mice are expressing preference for
OXY). Nevertheless, behaviors and factor analyses of NAL-trained
mice on the NAL side can be found in Supplementary Tables
S1, S2. Three-Way ANOVAs (Treatment, Strain, and Sex) were
conducted and we only observed one significant three-way inter-
action with regard toOXY vs. SAL (D9-D1 visits; data not shown).
We did not observe any three-way interactions with regard to
NAL vs. SAL. Therefore, for all subtraction variables, we collapsed
across Sex and focused on two-way interactions followed by
t-tests whereby the significance thresholds were adjusted for the
four main comparisons (p < 0.0125; 0.05/4 = 0.0125). The four
comparisons included (1) the strain comparison in SAL-trained
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mice; (2) the strain comparison in drug-treated mice; (3) the
treatment comparison for the J strain; and (4) the treatment
comparison for the NJ strain.
EXPLORATORY FACTOR ANALYSIS
Exploratory factor analysis is a multivariate statistical method
used to reduce the data from a larger set of variables into smaller
sets of intercorrelated variables called common factors, providing
insight into the underlying data structure. Video tracking anal-
ysis permits the ability to generate nearly an infinite number of
variables containing varying degrees of correlation that can con-
tribute to our understanding of the primary outcome variables
under consideration: D8-D1 time and D9-D1 time. We included
12 variables in each factor analysis, including six main variables
[distance, time, mean visit time, visits, rotations (see description
for rotations in Figure 1A)], and freezing bouts (defined as amin-
imum of 250ms of immobility) that comprised six subtraction
variables during drug-free CPP/CPA assessment (D8-D1) and
state-dependent CPP/CPA assessment (D9-D1). Factor analysis
was conducted for OXY-trained vs. SAL-trained mice for the OXY
(right)-paired side (the side where preference-related behaviors
were expressed) and for NAL-trained vs. SAL-trained mice for the
SAL (left)-paired side (the side of retreat where avoidance-related
behaviors were expressed).
Exploratory factor analysis was conducted with the R pack-
age “psych” using the “fa” factor analysis function. Variables
were standardized to z scores prior to generating the correla-
tion matrix. We employed a minimum residual fitting procedure
(“minres”) to minimize the squared residual of the factor model.
We used the “Varimax” function for orthogonal rotation of the
matrix whereby the solution for data reduction does not allow
the factors to be correlated. Varimax rotation maximizes the sum
of the variances of the squared correlations (loadings) between
variables and factors, yielding a simple structure to the data that
most efficiently loads each variable onto as few factors as pos-
sible. Factors with eigenvalues greater than one were included
in the analysis. Using these criteria, the 12 behavioral variables
(see below) loaded onto anywhere between three to five factors,
depending on the treatment and/or strain.
RESULTS
BEHAVIORAL ANALYSIS
F statistics from ANOVAs for treatment x strain interactions and
main effects where relevant are reported followed by t-tests for
the relevant comparisons. Means and S.E.M. are provided for the
12 subtraction variables for OXY vs. SAL in Table 1 (right side;
preference side) and for NAL vs. SAL in Table 3 (left side; the side
of retreat).
Days 2 and 4 of OXY-CPP training
In comparing changes in behavior in OXY- vs. SAL-treated mice
between Days 2 and 4 of training, we did not observe any three-
way (Treatment, Strain, Sex) or two-way (Treatment, Strain)
interactions as measured via changes in distance, rotations, or
freezing bouts [F(1, 207) < 1] nor did we observe any interactions
when ANOVAs were run for the individual Day 2 or Day 4
variables [F(1, 207) ≤ 1; data not shown].
OXY-CPP and state-dependent CPP
For both D8-D1 time and D9-D1 time, there was a main effect
of Treatment [F(1, 207) = 12.7, 54.9; p = 0.004, 3.6 × 10−33],
indicating significant drug-free and state-dependent OXY-CPP
(Table 1) that was not dependent on Strain [F(1, 207) < 1] nor
a Treatment × Strain interaction [F(1, 207) < 1]. To summarize,
we did not observe any strain differences in our primary outcome
measures of opioid reward.
Days 2 and 4 of NAL-CPA training
In examining strain differences in behavioral training with
NAL vs. SAL between Days 2 and 4, there was a sig-
nificant Treatment x Strain interaction for D4-D2 freezing
bouts [F(1, 180) = 3.9; p = 0.05] that was explained by NAL-
trained J mice showing an increase in the number of freezing
bouts relative to SAL-trained J mice [t(98) = 3.2; p = 0.0017]
and relative to NAL-trained NJ mice [t(85) = 3.1; p = 0.0023;
Figure 2A]. In contrast, NAL-trained NJ mice did not show
an increase in the number of freezing bouts relative to SAL-
trained NJ mice [t(87) < 1; Figure 2A]. Importantly, there was
no strain difference between SAL-trained mice, indicating that
this change in behavior was specific to a previous history of NAL
treatment.
NAL-CPA and concomitant variables
For the SAL-paired side (the side of retreat), there was a signifi-
cant Treatment × Strain interaction for D8-D1 time and D8-D1
visits [F(1, 180) = 9.8, 7.6; p = 0.002, 0.006]. The D8-D1 time
interaction was explained by NAL-trained J mice exhibiting a
significant increase in time spent on the side of retreat (or i.e.,
a decrease in time spent on the NAL-paired side as illustrated
in Figure 2B) relative to SAL-trained J mice [t(98) = 7.1; p =
2.5 × 10−10] and relative to NAL-trained NJ mice [t(85) = 3.9;
p = 0.0002; Figure 2B]. NAL-trained NJ mice did not show sig-
nificant NAL-CPA relative to SAL-trained NJ mice [t(86) =2.2,
p > 0.0125; Figure 2B]. The interaction for D8-D1 visits was
explained by NAL-trained J mice exhibiting a significant decrease
in visits relative to SAL-trained J mice [t(98) = 4.8; p = 5.9 ×
10−6] and relative to NAL-trained NJ mice [t(85) = 5.2; p =
1.4 × 10−6; Figure 3A]. Importantly, there were no strain dif-
ferences between SAL-trained mice for D8-D1 time or visits
(Figures 2B, 3A), demonstrating the specificity of the strain dif-
ference to prior NAL training. Although the Treatment x Strain
interaction was not significant for D8-D1 visit time [F(1, 180) =
2.9; p = 0.092; Figure 3B], we present the results so that they can
be compared with the state-dependent results in Figure 3E (see
below).
For D8-D1 freezing bouts, the Treatment x Strain inter-
action was not significant [F(1, 180) = 2.2; p = 0.14]; however,
NAL-trained J mice clearly demonstrated a highly significant
increase in the number of freezing bouts relative to SAL-trained
J mice [t(98) = 5.8; p = 1.1 × 10−7] and relative to NAL-trained
NJ mice [t(85)= 4.2; p = 7.0 × 10−5]. NAL-trained NJ mice
also showed a significant increase in the number of freezing
bouts relative to SAL-trained NJ mice [t(86) = 3.2; p = 0.002;
Figure 3C], contributing to the lack of Treatment × Strain
interaction. Each pair-wise comparison survived the corrected
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FIGURE 2 | Development of freezing bouts in J mice during NAL
training predicts NAL-CPA for the NAL-paired side. (A) NAL-trained J
mice, but not NAL-trained NJ mice (black bars) demonstrated a significant
instatement of NAL-induced freezing bouts from the first to second training
trial relative to SAL-trained J mice (white bars). (B,C) This behavior
predicted the strain-dependent enhancement of drug-free and
state-dependent NAL-CPA. ∗Significantly different from SAL control mice
(p < 0.0125; Bonferroni-corrected significance threshold). #Significantly
different from NAL-trained NJ mice (p < 0.0125). Data are presented as the
mean ± S.E.M.
FIGURE 3 | Conditioned and state-dependent avoidance behaviors on
the SAL-paired side (the side of retreat) during NAL-CPA. (A–C)
Conditioned, drug-free changes in visits, visit time, and freezing bouts on
the SAL-paired side from Day 1 to Day 8 (D8-D1) in NAL-trained (black bars)
vs. SAL-trained mice (white bars). (D–F) State-dependent changes in the
number of visits, visit time, and freezing bouts on the SAL-paired side from
Day 1 to Day 9 (D9-D1) following an injection of the treatment that was
received during Days 2 and 4 of training [either NAL (4mg/kg, i.p. black
bars) or SAL (i.p. white bars)]. ∗Significantly different from SAL control
mice (p < 0.0125; Bonferroni-corrected significance threshold).
#Significantly different from NAL-trained NJ mice (p < 0.0125). Data are
presented as the mean ± S.E.M.
significance threshold for multiple comparisons (p < 0.0125);
thus, we conclude that J mice are more sensitive to NAL-
induced conditioned freezing bouts that can be predicted by the
J-specific development of freezing bouts during NAL training
(Figure 2A).
State-dependent NAL-CPA and concomitant variables
For D9-D1 on the SAL-paired side, significant Treatment x Strain
interactions were identified for D9-D1 visits, visit time, and
freezing bouts [F(1,180) = 13.0, 5.2, 4.0; p = 0.004, 0.023, 0.046].
These interactions were explained by NAL-trained Jmice showing
Frontiers in Behavioral Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 450 | 5
Kirkpatrick and Bryant Factor analysis of CPP/CPA
a decrease in visits, an increase in visit time, and an increase in
freezing bouts relative to SAL-trained J mice [t(98) = 5.9, 6.3, 6.8;
p = 6.3 × 10−8, 2.1 × 10−8, 1.1 × 10−9] and relative to NAL-
trained NJ mice [t(85) = 7.0, 2.8, 3.2; p = 6.4 × 10−10, 0.0055,
0.0017; Figures 3D–F]. NAL-trained NJ mice also showed a sig-
nificant increase in freezing bouts relative to SAL-trained NJ
mice [t(86) = 3.4; p = 0.001; Figure 3F] but not any of the other
behaviors (p > 0.0125; Figures 3D,E). To summarize, J mice are
also more sensitive to the concomitant behaviors that support
state-dependent NAL-CPA.
FACTOR ANALYSIS
SAL-trained mice: Right and left sides
With regard to SAL-trained J mice, we identified four identical
factors between the right side (OXY preference side) and left side
(NAL side of retreat) that we named “ Time,”  Freezing,”
“D8-D1 Activity,” and “D9-D1 Activity” (Tables 2A, 4A). For NJ
mice, the behavioral structure of the left side (side of retreat) was
identical to the J strain (Table 4B) and contained the same four
factors. However, for the right side (preference side), change in
time loaded with additional variables, leading us to re-name this
factor “ Time and Rotations” that also included D9-D1 distance
(Table 2B). Accordingly, we also re-named the D9-D1 Activity
factor to, “D9-D1Visit Behavior” (Table 2B).
OXY-trained mice: OXY-paired side (preference side)
With regard to drug-free OXY-CPP (D8-D1 time), D8-D1 dis-
tance and D8-D1 rotations all loaded onto the same factor for
both strains. We named this factor, “Conditioned Opioid-Like
Behavior” (Tables 2C,D). Importantly, co-loading of D8-D1 time
with opioid-like activity was specific to the OXY-paired side—
for the SAL-paired side, there were distinct “D8-D1 Time” and
“D8-D1 Activity” factors (data not shown). These observations
indicate that conditioned reward and conditioned opioid-like
Table 2 | Factor analysis of OXY-CPP on OXY-paired preference side (right side).
(A) SAL-trained B6J mice (B) SAL-trained B6NJ mice
 Time  Freez. D8-D1 D9-D1 –  Time  Freez. D8-D1 D9-D1 –
Act. Act. and Rot. Act. Visit Beh.
% variance 20.0 18.0 23.6 21.8 26.9 16.5 15.3 16.7
D8-D1 time 0.74 0.52
D8-D1 visit time −0.65 −0.87
D8-D1 visits 0.85 0.53
D8-D1 rot. 0.64 0.52
D8-D1 dist. 0.95 0.65
D8-D1 freez. 0.98 0.99
D9-D1 time 0.79 0.69
D9-D1 visit time 0.83 0.99
D9-D1 visits 0.77 −0.64
D9-D1 rot. 0.91 0.65
D9-D1 dist. 0.98 0.86
D9-D1 freez. 0.93 0.91
(C) OXY-trained B6J mice (D) OXY-trained B6NJ mice
Cond. Opioid- State-Dep. State-Dep.  Freez. D8-D1 Cond. Opioid- State-Dep. State-Dep.  Freez. D8-D1
Like Beh. Pref. Opioid Act. Visit Time Like Beh. Pref. Opioid Act. Visit Beh.
% variance 18.8 16.0 16.4 13.9 13.6 21.7 12.6 16.6 19.3 16.5
D8-D1 time 0.58 0.85
D8-D1 visit time 0.97 0.91
D8-D1 visits 0.61 −0.90
D8-D1 rot. 0.69 0.84
D8-D1 dist. 0.95 0.85
D8-D1 freez. 0.98 0.81
D9-D1 time 0.72 0.66
D9-D1 visit time 0.58 0.84
D9-D1 visits −0.95 −0.64
D9-D1 rot. 0.81 0.95
D9-D1 dist. 0.96 0.92
D9-D1 freez. 0.75 0.91
Freez., freezing bouts; Act., activity, Cond., conditioned; Dep., dependent; Beh., behavior; Pref., preference; dist., distance; rot., rotations.
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activity measures co-vary in the drug-paired context. For J mice,
D8-D1 visits also loaded positively onto “Conditioned Opioid-
Like Behavior” (Table 2C). For NJ mice, D8-D1 visits loaded
negatively with D8-D1 visit time onto a factor that we termed,
“D8-D1 Visit Behavior” (Table 2D).
With regard to state-dependent OXY-CPP, D9-D1 time and
D9-D1 visit time loaded onto a single factor for both J and
NJ that we named, “State-Dependent Preference” (Tables 2C,D).
Furthermore, for J mice, D9-D1 visits loaded negatively onto this
same factor whereas for NJ mice, D9-D1 visits loaded onto 
Freezing. For both strains, D9-D1 distance and rotations clearly
loaded onto a single, discrete factor which we named, “State-
Dependent Opioid Activity” (Tables 2C,D).
Similar to SAL-trained mice (Tables 2A,B, 4A,B), for OXY-
trained J and NJ mice, the change in freezing bouts for Days 8
and 9 loaded onto a “ Freezing” factor (Tables 2C,D), indicating
that freezing is not associated with the expression of conditioned
or state-dependent opioid reward.
NAL-trained mice: SAL-paired side (the side of retreat)
For aversion-prone J mice (Figure 2B), the relationship between
aversion and freezing was extensive whereby a single factor
contained conditioned (D8-D1) and state-dependent (D9-D1)
changes in time and freezing bouts as well as visit time; we
named this factor, “Avoidance and Freezing” (Table 4C). For the
less aversive NJ strain (Figure 2B), “Conditioned Avoidance and
Freezing” and “State-Dependent Avoidance and Freezing” formed
separate factors (Table 4D). With regard to activity measures, for
the aversion-prone J strain, there were clearly two distinct activity
factors that we termed “D8-D1 Activity” and “D9-D1 Activity”
(Table 4C) whereas for the less aversive NJ strain, there was a
single “ Activity” factor for both days (Table 4D).
Behavioral values and factor analysis of NAL-trained mice on
the NAL-paired side can be found in Supplementary Tables S1, S2.
The results are similar whereby freezing loads onto measures of
time for both strains (Table S2) rather than loading by itself in
SAL-treated mice (Table 2).
DISCUSSION
B6 substrains showed a comparable level of opioid reward as
measured via drug-free and state-dependent OXY-CPP (Table 1).
However, J mice demonstrated a three-fold enhanced sensitivity
to opioid aversion relative to NJ mice as measured via NAL-CPA
(Table 3; Figure 2). The selectivity of the strain difference for the
aversive properties of an opioid receptor antagonist and not the
rewarding properties of a mu opioid receptor agonist suggests a
difference in tonic release of endogenous opioids (Skoubis et al.,
2005) or perhaps stress-induced release of endogenous opioids
during CPP training that, in turn, leads to an adaptation at the
receptor level [e.g., constitutive activity of the mu opioid receptor
(Shoblock and Maidment, 2006)] or at the downstream level of
the aversion neurocircuitry. In support, endogenous enkephalins
are necessary for NAL-CPA (Skoubis et al., 2005) but not opioid-
induced CPP (Marquez et al., 2006) whereas mu opioid recep-
tors are necessary for both phenotypes (Matthes et al., 1996;
Skoubis et al., 2001). Interestingly, NAL-CPA-prone J mice also
drink more ethanol than C57BL/6N mice from the Charles River
Table 3 | Change in behavior on the SAL-paired side (left side; the side
of retreat) following SAL or NAL training.
SAL training
Variable J (S.E.M.) NJ (S.E.M.)
N = 56 N = 45
(30 F, 26 M) (25 F, 20 M)
D8-D1 time (s) −17.6 (20.1) −12.0 (23.0)
D8-D1 visit time (s) 1.2 (1.2) 1.3 (1.7)
D8-D1 visits −4.8 (3.5) −0.7 (2.9)
D8-D1 rotations −7.0 (1.4) −6.6 (1.6)
D8-D1 distance (m) −6.6 (1.1) −5.1 (1.1)
D8-D1 freezing bouts 0.1 (18.7) −9.5 (22.0)
D9-D1 time (s) −0.1 (28.0) 3.6 (29.9)
D9-D1 visit time (s) 3.2 (1.0) 2.5 (1.3)
D9-D1 visits −11.3 (4.0) −6.5 (2.6)
D9-D1 rotations −5.5 (2.6) −8.3 (1.7)
D9-D1 distance (m) −8.1 (1.7) −6.9 (1.0)
D9-D1 freezing bouts −0.4 (19.0) 4.7 (22.6)
NAL training
Variable J (S.E.M.) NJ (S.E.M.)
N = 44 N = 43
(22 F, 22 M) (23 F, 20 M)
D8-D1 time (s) 225.5 (26.5) 73.8 (28.6)
D8-D1 visit time (s) 7.6 (1.1) 2.5 (1.2)
D8-D1 visits −22.6 (2.9) −2.7 (2.6)
D8-D1 rotations −10.1 (1.7) −5.9 (2.0)
D8-D1 distance (m) −9.1 (1.0) −5.8 (1.0)
D8-D1 freezing bouts 128.3 (11.9) 62.3 (10.4)
D9-D1 time (s) 299.6 (42.4) 174.2 (42.9)
D9-D1 visit time (s) 17.8 (2.0) 9.7 (1.0)
D9-D1 visits −42.4 (3.1) −13.8 (2.7)
D9-D1 rotations −13.3 (1.9) −9.1 (1.8)
D9-D1 distance (m) −15.9 (1.2) −9.8 (1.1)
D9-D1 freezing bouts 177.1 (16.5) 107.0 (14.0)
The mean ± S.E.M. and sample size (N; F, females; M, males) for each strain (J,
NJ) and treatment (SAL, NAL) is presented for each of the 12 variables used in
factor analysis.
vendor (Bryant et al., 2008) and this behavior is in part medi-
ated by endogenous opioids (Racz et al., 2008). Future studies will
examine the potential for B6 strain differences in basal and drug-
induced endogenous opioid levels as a potential neurochemical
mechanism for variation in motivational behaviors.
Irrespective of strain, we observed very different behav-
ioral architectures underlying OXY preference vs. NAL aversion.
Following OXY training, OXY-CPP (D8-D1 time) loaded onto
the same factor as change in distance and rotations for both
strains (Tables 2A,B). Opioid-induced rotations (Figure 1A), or
“circling” is a stereotypic behavior that is induced by opioid
administration (Iwamoto and Way, 1977; Morihisa and Glick,
1977; Seidel et al., 1979; Mickley et al., 1990; Bryant et al., 2009;
Hodgson et al., 2010) and its behavioral pattern can be expressed
as a conditioned opioid-like placebo response (Bryant et al.,
2009). Our observations indicate that mice expressing drug-free
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Table 4 | Factor analysis of NAL-CPA on the SAL-paired side (left side; the side of retreat).
(A) SAL-trained J mice (B) SAL-trained NJ mice
 Time  Freez. D8-D1 D9-D1  Time  Freez. D8-D1 D9-D1
Act. Act. Act. Act.
% variance 19.6 17.4 20.7 21.7 17.9 17.2 20.9 21.5
D8-D1 time 0.82 0.54
D8-D1 visit time −0.68 −0.79
D8-D1 visits 0.96 0.77
D8-D1 rot. 0.21 0.56
D8-D1 dist. 0.76 0.84
D8-D1 freez. 0.96 0.97
D9-D1 time 0.94 0.74
D9-D1 visit time 0.75 0.88
D9-D1 visits 0.75 0.61
D9-D1 rot. 0.86 0.77
D9-D1 dist. 0.98 0.95
D9-D1 freez. 0.97 0.88
(C) NAL-trained J mice (D) NAL-trained NJ mice
Avoid. D8-D1 D9-D1 Cond. Avoid. State-Dep. Avoid.  Act.
and Freez. Act. Act. and Freez. and Freez.
% variance 32.8 19.3 19.5 25.2 25.6 30.7
D8-D1 time 0.73 0.77
D8-D1 visit time 0.73 0.80
D8-D1 visits 0.64 −0.61
D8-D1 rot. 0.76 0.76
D8-D1 dist. 0.92 0.83
D8-D1 freez. 0.72 0.90
D9-D1 time 0.85 0.80
D9-D1 visit time 0.82 0.92
D9-D1 visits 0.74 0.63
D9-D1 rot. 0.68 0.76
D9-D1 dist. 0.90 0.90
D9-D1 freez. 0.86 0.81
Freez., freezing bouts; Act., activity, Cond., conditioned; Dep., dependent; Beh., behavior; Pref., preference; dist., distance; rot., rotations.
conditioned opioid reward behave in a manner that is similar to
having received an opioid injection. This “Conditioned Opioid-
Like Behavior” factor was context-specific; on the SAL-paired side
this factor dissolved into two separate activity- and time-based
factors (data not shown), similar to SAL control mice (Table 2).
We hypothesize that expectation-induced placebo-like behavioral
responding both contribute to and in turn, are reinforced by the
conditioned, incentive-motivational properties of the tactile cues
(Figure 1A) that were paired with OXY (Meyer et al., 2012), thus
accounting for OXY-CPP.
With regard to state-dependent OXY-CPP following an OXY
challenge (D9-D1 time), Conditioned Opioid-Like Behavior dis-
solved into separate factors that we termed State-Dependent
Opioid Activity and State-Dependent Preference (Tables 2C,D).
I.e., under the influence of OXY, opioid-induced activity was dis-
sociable from conditioned reward. Interestingly, although there
was a large, state-dependent increase in the number of visits
following OXY administration that was accompanied by a two
to three-fold enhancement of OXY-CPP in both strains (D9-D1
vs. D8-D1; Table 1), here, in J mice the change in visits loaded
negatively (−0.95) onto the State-Dependent Preference factor
containing time and visit time rather than positively (0.60) as
was observed during drug-free OXY-CPP (Table 2C). We hypoth-
esize that the positive link between visits and preference during
the drug-free state (D8-D1) identifies “visits” as a drug seeking
behavior in the absence of drug. On Day 9 (D9-D1), the need
for drug seeking is obviated because mice are under the influence
of OXY.
During NAL training for NAL-CPA, we discovered that
although acute NAL treatment did not induce any change in
the number of freezing bouts relative to SAL-treated mice on
Day 2, following the second injection on Day 4, the J strain,
but not the NJ strain showed a significant increase in the
number of freezing bouts relative to the first NAL administra-
tion and relative to SAL-treated mice (Figure 2A). There are
two possible explanations for this result. One is that there is
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a neuropharmacological instatement of NAL-induced freezing
bouts that requires prior NAL exposure, resulting in a behavioral
pharmacological response that is akin to a sensitization phe-
nomenon. A second possibility is that this behavior represents a
Pavlovian conditioned response that is expressed in anticipation
of an aversive stimulus (naloxone)—similar to context-dependent
freezing in anticipation of an aversive electric shock (Curzon
et al., 2009). Given the present data, it is not possible to conclude
whether the induction of freezing bouts during NAL training is
a learned response because our experimental design did not con-
tain a treatment group that received a NAL injection on Day 2 and
a SAL injection on Day 4. Nevertheless, the subsequent results on
Day 8 support the hypothesis that the development of a J-specific
increase in freezing bouts during NAL training is not a neu-
ropharmacological response, but rather, is a learned motivational
response that is subsequently expressed to a greater degree in J
mice vs. NJ mice in the absence of NAL (Figure 3C). Thus, in this
case strain differences (and likely genetic differences) in the devel-
opment of freezing bouts during behavioral training with NAL
can be used to predict strain differences in behavioral expression
of the dysphoric properties of NAL as measured via NAL-CPA
(Figure 2B) and other concomitant behaviors (Figure 3).
We observed a robust strain difference in NAL-CPA
(Figure 2B) and very different factor loadings for NAL-CPA
vs. OXY-CPP (Tables 4C,D vs. Tables 2C,D). In the aversion-
prone J strain, NAL-CPA during both the drug-free (D8-D1)
and drug-induced state (D9-D1) loaded onto a single, distinct
“Avoidance and Freezing” factor that contained an increase in
time spent avoiding the NAL-paired side (Figures 2B,C; Table 3),
an increase in visit time and an increase in the number of freezing
bouts (Figure 3; Table 3). Two other distinct factors for the
J strain clearly comprised activity-based measures (distance,
rotations, and visits; Figures 3A,D), thus revealing an important
distinction between the behavioral structure of conditioned
aversion vs. conditioned reward. For the aversion-resistant NJ
strain, drug-free (D8-D1 time) and drug-induced NAL-CPA
(D9-D1 time) loaded onto two separate factors, Conditioned
Aversion and State-Dependent Aversion, each of which contained
the same major variables as the J strain (time, freezing bouts,
and visit time; Table 4D). Finally, for the NJ strain, a single, third
factor comprised change in activity-based measures for Day 8
and Day 9 (Table 4D).
To summarize, we identified enhanced NAL-CPA and other
concomitant behaviors in J vs. NJ mice as well as a unique behav-
ioral architecture that defined opioid reward vs. opioid aversion.
The expression of opioid reward during the drug-free state may
be described as one that co-varies with conditioned opioid-like
responses in the drug-paired context. In contrast, state-dependent
opioid reward does not co-vary with opioid-induced locomotor
activity but rather, co-varies with increased visit time. Opioid
aversion can best be characterized by longer periods of condi-
tioned and state-dependent avoidance of the NAL-paired side
coupled with a marked increase in the number of freezing bouts
that is foreshadowed during drug training and is co-expressed
with the enhanced avoidance behaviors that underlie NAL-CPA.
These results do not modify the interpretation of the main find-
ing (enhanced NAL-CPA in J mice) nor do they suggest that any
specific concomitant behavior could replace the measurement
of change in time as the primary measure reward or aversion;
however, they do provide new insight into the development
and expression of the behavioral structure of conditioned opi-
oid reward and aversion and highlight additional variables (e.g.,
freezing bouts) and relationships that can be examined in future
CPP and CPA studies.
This study is limited by the number of doses and types of drugs
that could be examined. Future studies examining the behavioral
structure of CPP and CPA induced by other pharmacological
agents, including psychostimulants, ethanol, and antipsychotics
could reveal important distinctions between different drug classes
and inform the underlying psychological nature of drug seek-
ing vs. drug avoidance behavior. Furthermore, the potential for
genetic differences underlying the behavioral structure of CPP
and CPA is an important consideration in forward genetic and
reverse genetic engineering experiments and could enrich the
interpretation of the data. Finally, because we observed robust
B6 substrain differences in NAL-CPA and associated behaviors
in the present study, we are currently collecting genotypes and
phenotypes from an F2 cross derived from these nearly identi-
cal substrains to facilitate the identification of QTLs and novel
genetic factors that contribute to NAL-CPA (Bryant et al., 2008);
this cross has recently been used to identify novel genetic factors
contributing to cocaine-induced behaviors (Kumar et al., 2013).
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